trending Market Intelligence /marketintelligence/en/news-insights/trending/swt-5y8_bulroq9nz0prhw2 content esgSubNav
In This List

ProQR prices common stock offering

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


ProQR prices common stock offering

ProQR Therapeutics NV priced an underwritten public offering of 5,750,000 ordinary shares at $15.75 each.

The Netherlands-based biopharmaceutical company expects to raise gross proceeds of about $90.6 million through the offering, which is expected to close Sept. 11, subject to customary closing conditions.

Underwriters have a 30-day option to buy up to 862,500 additional ordinary shares at the offering price.

Citigroup, Evercore ISI and RBC Capital Markets are acting as joint book runners for the offering, with H.C. Wainwright & Co. and Chardan as co-managers. Kempen & Co. is acting as ProQR's European financial adviser for the offering.